Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 2
1972 8
1973 9
1974 9
1975 20
1976 11
1977 10
1978 13
1979 14
1980 14
1981 13
1982 22
1983 8
1984 24
1985 22
1986 14
1987 22
1988 21
1989 26
1990 31
1991 20
1992 23
1993 14
1994 22
1995 28
1996 20
1997 31
1998 25
1999 22
2000 18
2001 19
2002 22
2003 22
2004 30
2005 25
2006 24
2007 32
2008 38
2009 52
2010 63
2011 74
2012 119
2013 166
2014 204
2015 255
2016 265
2017 303
2018 329
2019 427
2020 554
2021 603
2022 621
2023 706
2024 721
2025 378

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,746 results

Results by year

Filters applied: . Clear all
Page 1
Ketamine for depression.
Jelen LA, Stone JM. Jelen LA, et al. Int Rev Psychiatry. 2021 May;33(3):207-228. doi: 10.1080/09540261.2020.1854194. Epub 2021 Feb 11. Int Rev Psychiatry. 2021. PMID: 33569971 Review.
Ketamine is a racemic mixture composed of equal amounts of (S)-ketamine and (R)-ketamine. ...A synopsis of some of the putative neurobiological mechanisms underlying ketamine's rapid-acting antidepressant effects is provided before finally outli …
Ketamine is a racemic mixture composed of equal amounts of (S)-ketamine and (R)-ketamine. ...A synopsis of some of the …
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr, Stahl S. McIntyre RS, et al. Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17. Am J Psychiatry. 2021. PMID: 33726522 Free PMC article. Review.
Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to providing hope to affected persons, these agents represent the first non-monoaminergic agents with proven rapid-onset ef …
Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression …
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.
Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Smith-Apeldoorn SY, et al. Lancet Psychiatry. 2022 Nov;9(11):907-921. doi: 10.1016/S2215-0366(22)00317-0. Lancet Psychiatry. 2022. PMID: 36244360 Review.
Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its ef …
Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strat …
Ketamine: Mechanisms and Relevance to Treatment of Depression.
Kim JW, Suzuki K, Kavalali ET, Monteggia LM. Kim JW, et al. Annu Rev Med. 2024 Jan 29;75:129-143. doi: 10.1146/annurev-med-051322-120608. Epub 2023 Sep 20. Annu Rev Med. 2024. PMID: 37729028 Free article. Review.
Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary line of treatment for this mental disorder, although the delayed response and incomplete efficacy in some patients highlight the nee …
Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary …
Oral ketamine for depression: An updated systematic review.
Meshkat S, Haikazian S, Di Vincenzo JD, Fancy F, Johnson D, Chen-Li D, McIntyre RS, Mansur R, Rosenblat JD. Meshkat S, et al. World J Biol Psychiatry. 2023 Sep-Oct;24(7):545-557. doi: 10.1080/15622975.2023.2169349. Epub 2023 Jan 31. World J Biol Psychiatry. 2023. PMID: 36651238 Review.
Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive disorder by single or repeated infusions. However, the accessibility and scalability of oral ketamine make it preferred over intrave …
Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive dis …
Long-term safety of ketamine and esketamine in treatment of depression.
Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Nikayin S, et al. Expert Opin Drug Saf. 2022 Jun;21(6):777-787. doi: 10.1080/14740338.2022.2066651. Epub 2022 Apr 19. Expert Opin Drug Saf. 2022. PMID: 35416105 Review.
INTRODUCTION: Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019. ...However, severe bladder pathology has not been r …
INTRODUCTION: Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic …
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Bahji A, Vazquez GH, Zarate CA Jr. Bahji A, et al. J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23. J Affect Disord. 2021. PMID: 33022440 Free PMC article.
BACKGROUND: Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. ...RR = 1.47), as well as lower dropouts (RR = 0.76 vs. RR = 1.37). CONCLUSIONS: Intravenous ketamine appears to be more efficacious than intranasal …
BACKGROUND: Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. ...RR = 1.47), a …
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.
Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, Di Vincenzo JD, Meshkat S, Ho RCM, Gill H, Teopiz KM, Cao B, Lee Y, McIntyre RS, Rosenblat JD. Alnefeesi Y, et al. J Psychiatr Res. 2022 Jul;151:693-709. doi: 10.1016/j.jpsychires.2022.04.037. Epub 2022 May 25. J Psychiatr Res. 2022. PMID: 35688035 Review.
Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The acute efficacy of ketamine in TRD has been demonstrated in replicated randomised-controlled trials (RCTs), but the generalizability of RCT data to real-world practice is l …
Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The acute efficacy of ketamine in T …
Ketamine for resistant depression: a scoping review.
Eduardo TQ, Angela A, Mateo L, Melanie LZ, Valentina PF, David C, Estefania C, Natalia RS, Andrés VC, Angel RO, Juan G, Juan P. Eduardo TQ, et al. Actas Esp Psiquiatr. 2022 May;50(3):144-159. Epub 2022 May 1. Actas Esp Psiquiatr. 2022. PMID: 35643973 Free PMC article.
Ketamine is a fast-acting anesthetic with hypnotic properties. Moreover, could potentially improve affective symptoms in patients with refractory depressive disorder. Objective. explore the scientific literature available until December 10, 2021, about the ef …
Ketamine is a fast-acting anesthetic with hypnotic properties. Moreover, could potentially improve affective symptoms in patients wit …
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.
Subramanian S, Haroutounian S, Palanca BJA, Lenze EJ. Subramanian S, et al. J Neurol Sci. 2022 Mar 15;434:120152. doi: 10.1016/j.jns.2022.120152. Epub 2022 Jan 14. J Neurol Sci. 2022. PMID: 35092901
Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. ...Many clinical trials have utilized intravenous or intranasal ketamine for treating depression and pain. Intravenous …
Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression …
5,746 results

Searches related to "ketamine depression"